150 related articles for article (PubMed ID: 35243381)
1. An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response.
Wang YN; Lee HH; Wei Y; Chu YY; Xia W; Wang M; Yu D; Hung MC
STAR Protoc; 2022 Mar; 3(1):101198. PubMed ID: 35243381
[TBL] [Abstract][Full Text] [Related]
2. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.
Lee HH; Wang YN; Xia W; Chen CH; Rau KM; Ye L; Wei Y; Chou CK; Wang SC; Yan M; Tu CY; Hsia TC; Chiang SF; Chao KSC; Wistuba II; Hsu JL; Hortobagyi GN; Hung MC
Cancer Cell; 2019 Aug; 36(2):168-178.e4. PubMed ID: 31327656
[TBL] [Abstract][Full Text] [Related]
3. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.
Bigelow E; Bever KM; Xu H; Yager A; Wu A; Taube J; Chen L; Jaffee EM; Anders RA; Zheng L
J Vis Exp; 2013 Jan; (71):. PubMed ID: 23328703
[TBL] [Abstract][Full Text] [Related]
5. Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
Silva MA; Triltsch N; Leis S; Kanchev I; Tan TH; Van Peel B; Van Kerckhoven M; Deschoolmeester V; Zimmermann J
J Pathol Clin Res; 2020 Apr; 6(2):124-137. PubMed ID: 31922656
[TBL] [Abstract][Full Text] [Related]
6.
Klümper N; Wüst L; Saal J; Ralser DJ; Zarbl R; Jarczyk J; Breyer J; Sikic D; Wullich B; Bolenz C; Roghmann F; Hölzel M; Ritter M; Strieth S; Hartmann A; Erben P; Wirtz RM; Landsberg J; Dietrich D; Eckstein M
Oncoimmunology; 2023; 12(1):2267744. PubMed ID: 37868689
[TBL] [Abstract][Full Text] [Related]
7. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
[TBL] [Abstract][Full Text] [Related]
8. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
9. Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Duncan DJ; Scott M; Scorer P; Barker C
PLoS One; 2019; 14(4):e0215393. PubMed ID: 30986253
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.
Grote HJ; Feng Z; Schlichting M; Helwig C; Ruisi M; Jin H; Scheuenpflug J; Gann CN; Su Z; Reck M; Vokes EE; Kerr KM
J Thorac Oncol; 2020 Aug; 15(8):1306-1316. PubMed ID: 32353599
[TBL] [Abstract][Full Text] [Related]
12. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
[TBL] [Abstract][Full Text] [Related]
13. Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry.
Haragan A; Liebler DC; Das DM; Soper MD; Morrison RD; Slebos RJC; Ackermann BL; Fill JA; Schade AE; Gosney JR; Gruver AM
Lab Invest; 2020 Jun; 100(6):874-886. PubMed ID: 31896815
[TBL] [Abstract][Full Text] [Related]
14. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Roach C; Zhang N; Corigliano E; Jansson M; Toland G; Ponto G; Dolled-Filhart M; Emancipator K; Stanforth D; Kulangara K
Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):392-7. PubMed ID: 27333219
[TBL] [Abstract][Full Text] [Related]
15. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Zhang J; Dang F; Ren J; Wei W
Trends Biochem Sci; 2018 Dec; 43(12):1014-1032. PubMed ID: 30287140
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Patel SP; Kurzrock R
Mol Cancer Ther; 2015 Apr; 14(4):847-56. PubMed ID: 25695955
[TBL] [Abstract][Full Text] [Related]
17. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.
Pérottet J; Le Goff E; Legoupil D; Quéré G; Schick U; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):161-165. PubMed ID: 32044885
[TBL] [Abstract][Full Text] [Related]
19. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Omenai SA; Ajani MA; Okolo CA
PLoS One; 2022; 17(2):e0263615. PubMed ID: 35139126
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
Ahn S; Kim KM
Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]